Ovarian cancer drug niraparib tested in 850 korean women
NCT ID NCT06086665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how effective and safe niraparib is for Korean women with epithelial ovarian cancer. It included 850 patients who took niraparib as maintenance therapy or as a later treatment. Researchers measured how long patients lived without their cancer getting worse and tracked side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center
Seoul, 138-736, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a custom mRNA vaccine keep ovarian cancer from coming back?
- Could centralized surgery boost ovarian cancer survival?
- Targeted drug hunts down cancer cells in advanced bladder cancer trial
- New PET tracer aims to spot hidden cancer spread in the abdomen